fortressbiotech.com
Checkpoint Therapeutics, Inc.
http://www.fortressbiotech.com/portfolio-companies/checkpoint-therapeutics.cfm
Mustang Bio, Inc. Raquo; Fortress companies. Raquo; checkpoint therapeutics. Checkpoint Therapeutics, Inc. For more information, please visit www.checkpointtx.com.
fortressbiotech.com
Fortress Biotech - Specializing in Acquiring, Developing and Commercializing Novel Pharmaceutical and Biotechnology Products
http://www.fortressbiotech.com//index.cfm
Mustang Bio, Inc. October 28, 2016:. Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in. October 17, 2016:. Journey Medical Corporation Launches Targadox™ Oral Immediate-Release Tablet for Treatment of Severe Acne. October 3, 2016:. Checkpoint Therapeutics Initiates Phase 1/2 Study of CK-101 – A Novel Third-Generation EGFR Inhibitor. September 23, 2016:. Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference. September 12, 2016:.
ir.checkpointtx.com
Overview | Checkpoint Therapeutics
http://ir.checkpointtx.com/CorporateProfile
SEC Filings and Financials. SEC Filings and Financials. Checkpoint Therapeutics to Present at the 29th Annual ROTH Conference. Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101. Checkpoint Therapeutics Initiates Phase 1/2 Study of CK-101 A Novel Third-Generation EGFR Inhibitor. Checkpoint Therapeutics, Inc. New York, NY 10014. S&P Global Market Intelligence. TERMS AND CONDITIONS OF USE. These Terms of Use are the entire agreement between the p...
ir.checkpointtx.com
Events | Checkpoint Therapeutics
http://ir.checkpointtx.com/event
SEC Filings and Financials. SEC Filings and Financials. Tuesday, March 14, 2017. 29th Annual ROTH Conference. No details are available for this event. 10 AM EST, 7 AM PST 03/14/2017. Tuesday, September 27, 2016. Ladenburg Thalmann 2nd Annual Healthcare Conference. No details are available for this event. S&P Global Market Intelligence. TERMS AND CONDITIONS OF USE. The Site does not represent an offer or solicitation with respect to the purchase or sale of any security. These Terms of Use are the entire a...
ir.checkpointtx.com
Press Releases | Checkpoint Therapeutics
http://ir.checkpointtx.com/news
SEC Filings and Financials. SEC Filings and Financials. Subscribe for Email Alerts. Subscribe to RSS feed. Checkpoint Therapeutics to Present at the 29th Annual ROTH Conference. Download - XLS - 3.5MB. Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101. Download - XLS - 3.5MB. Checkpoint Therapeutics Initiates Phase 1/2 Study of CK-101 A Novel Third-Generation EGFR Inhibitor. Download - XLS - 3.5MB. Download - XLS - 3.5MB. Displaying 1 to 5.
ir.checkpointtx.com
Information Request | Checkpoint Therapeutics
http://ir.checkpointtx.com/inforequest
SEC Filings and Financials. SEC Filings and Financials. To join our mailing list, please complete your contact information and email address below. If you have any questions or comments, please submit your request to ir@checkpointtx.com. This form submits information via e-mail which is inherently insecure. Please do not include ANY personal information that you do not wish to be shared with others. S&P Global Market Intelligence. TERMS AND CONDITIONS OF USE. These Terms of Use are the entire agreement b...
fortressbiotech.com
Fortress Biotech - Specializing in Acquiring, Developing and Commercializing Novel Pharmaceutical and Biotechnology Products
http://www.fortressbiotech.com/portfolio-companies/altamira-bio.cfm
Mustang Bio, Inc. October 28, 2016:. Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in. October 17, 2016:. Journey Medical Corporation Launches Targadox™ Oral Immediate-Release Tablet for Treatment of Severe Acne. October 3, 2016:. Checkpoint Therapeutics Initiates Phase 1/2 Study of CK-101 – A Novel Third-Generation EGFR Inhibitor. September 23, 2016:. Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference. September 12, 2016:.
ir.checkpointtx.com
FAQs | Checkpoint Therapeutics
http://ir.checkpointtx.com/FAQ
SEC Filings and Financials. SEC Filings and Financials. Where are the Company headquarters located? Our headquarters are located in New York City. Our mailing address is 2 Gansevoort Street, 9th Floor, New York, NY 10014, USA. Where is the Company incorporated? The Company is incorporated in Delaware. Who is the Company's transfer agent? VStock Transfer, LLC. Woodmere, NY 11598. I've lost my stock certificates. How do I replace them? I've moved. How do I notify the Company of my new address? THE SITE AND...
ir.checkpointtx.com
SEC Filings | Checkpoint Therapeutics
http://ir.checkpointtx.com/docs
SEC Filings and Financials. SEC Filings and Financials. Please click to return to the document group list. View Insider related Regulatory Filings: Forms 3, 4 and 5. View Document Grouping descriptions. Checkpoint Therapeutics, Inc. 8-K filed by Checkpoint Therapeutics (CKPT) covering Entry into a Material Definitive Agreement. 8-K filed by Checkpoint Therapeutics (CKPT) covering Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Oliviero James F III.